全文获取类型
收费全文 | 21779篇 |
免费 | 2070篇 |
国内免费 | 382篇 |
专业分类
耳鼻咽喉 | 121篇 |
儿科学 | 811篇 |
妇产科学 | 413篇 |
基础医学 | 1806篇 |
口腔科学 | 639篇 |
临床医学 | 1813篇 |
内科学 | 3524篇 |
皮肤病学 | 226篇 |
神经病学 | 1795篇 |
特种医学 | 1445篇 |
外科学 | 2011篇 |
综合类 | 1513篇 |
现状与发展 | 1篇 |
一般理论 | 2篇 |
预防医学 | 4050篇 |
眼科学 | 228篇 |
药学 | 1559篇 |
4篇 | |
中国医学 | 264篇 |
肿瘤学 | 2006篇 |
出版年
2024年 | 21篇 |
2023年 | 446篇 |
2022年 | 415篇 |
2021年 | 845篇 |
2020年 | 969篇 |
2019年 | 926篇 |
2018年 | 838篇 |
2017年 | 860篇 |
2016年 | 815篇 |
2015年 | 767篇 |
2014年 | 1325篇 |
2013年 | 1556篇 |
2012年 | 1198篇 |
2011年 | 1274篇 |
2010年 | 965篇 |
2009年 | 1004篇 |
2008年 | 987篇 |
2007年 | 1097篇 |
2006年 | 956篇 |
2005年 | 916篇 |
2004年 | 834篇 |
2003年 | 771篇 |
2002年 | 595篇 |
2001年 | 465篇 |
2000年 | 366篇 |
1999年 | 321篇 |
1998年 | 253篇 |
1997年 | 205篇 |
1996年 | 170篇 |
1995年 | 225篇 |
1994年 | 214篇 |
1993年 | 187篇 |
1992年 | 209篇 |
1991年 | 169篇 |
1990年 | 111篇 |
1989年 | 109篇 |
1988年 | 123篇 |
1987年 | 91篇 |
1986年 | 84篇 |
1985年 | 114篇 |
1984年 | 73篇 |
1983年 | 54篇 |
1982年 | 65篇 |
1981年 | 51篇 |
1980年 | 45篇 |
1979年 | 25篇 |
1978年 | 39篇 |
1977年 | 31篇 |
1976年 | 15篇 |
1975年 | 11篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
12.
Stephanie H. Ameis John D. Haltigan Rachael E. Lyon Amanda Sawyer Pat Mirenda Connor M. Kerns Isabel M. Smith Tracy Vaillancourt Joanne Volden Charlotte Waddell Lonnie Zwaigenbaum Teresa Bennett Eric Duku Mayada Elsabbagh Stelios Georgiades Wendy J. Ungar Anat Zaidman-Zait Meng-Chuan Lai Peter Szatmari for the Pathways in ASD Study Team 《Journal of child psychology and psychiatry, and allied disciplines》2022,63(5):553-562
13.
Patrick Demkowicz BS Renelle Pointdujour-Lim MD Sofia Miguez BA Yesung Lee BS Bailey S. C. L. Jones BS Christopher A. Barker MD Marcus Bosenberg MD PhD David H. Abramson MD Alexander N. Shoushtari MD Harriet Kluger MD Jasmine H. Francis MD Mario Sznol MD Mathieu F. Bakhoum MD PhD 《Cancer》2023,129(20):3275-3286
14.
《Revista de gastroenterologia de Mexico》2022,87(1):52-58
IntroductionThe sofosbuvir-velpatasvir (SOF/VEL) combination is a direct-acting antiviral therapy that is authorized and available in Mexico, making the performance of a real-world multicenter study that evaluates the sustained virologic response at 12 weeks post-treatment a relevant undertaking.MethodsA retrospective review of the case records of 241 patients seen at 20 hospitals in Mexico was conducted to assess hepatitis C treatment with the SOF/VEL combination (n = 231) and the sofosbuvir/velpatasvir/ribavirin (SOF/VEL/RBV) combination (n = 10). The primary efficacy endpoint was the percentage of patients that achieved SVR at 12 weeks after the end of treatment.ResultsOverall SVR was 98.8% (95% CI 97.35-100%). Only three patients did not achieve SVR, two of whom had cirrhosis and a history of previous treatment with peg-IFN. Of the subgroups analyzed, all the patients with HIV coinfection, three patients with genotype 3, and the patients treated with the SOF/VEL/RBV combination achieved SVR. The subgroups with the lower success rates were patients that were treatment-experienced (96.8%) and patients with F1 fibrosis (95.5%). The most frequent adverse events were fatigue, headache, and insomnia. No serious adverse events were reported.ConclusionTreatments with SOF/VEL and SOF/VEL/RBV were highly safe and effective, results coinciding with those of other international real-world studies. 相似文献
15.
16.
17.
This commentary reviews top advances in hepatobiliary cancer research in 2021–2022, focusing on leveraging immunotherapeutics in combination with other therapies earlier in the disease course and targeted to patient's individualized biomarkers that may predict response or resistance to checkpoint inhibitors. 相似文献
18.
Signe Holst Søegaard Klaus Rostgaard Mads Kamper-Jørgensen Kjeld Schmiegelow Henrik Hjalgrim 《International journal of cancer. Journal international du cancer》2023,152(9):1817-1826
Childhood acute lymphoblastic leukaemia (ALL) is suggested to result from a dysregulated immune response to infections in children with a preleukaemic state. Childcare in early life supposedly may protect against childhood ALL by facilitating sufficient exposure to infections to stimulate and ensure normal maturation of the immune system. We assessed the association between childcare attendance before age 2 years and risk of childhood ALL in a register-based cohort study, including all children aged 2 to 14 years born in Denmark during 1991 to 2014 with available childcare information recorded in the Danish Childcare Database (n = 1 116 185). Cox regression was used to estimate hazard ratios (HRs) comparing children enrolled in childcare and children not enrolled before age 2 years. Further, we assessed the association according to age at enrolment, type of childcare facility and specific ALL subtypes. During 10 460 811 person-years of follow-up, 460 children developed ALL at ages 2 to 14 years. Of these, 57 (12.4%) never attended childcare before age 2 years compared with 10.6% in the total cohort. Compared with homecare, childcare attendance before age 2 years was associated with a statistically non-significantly, marginally decreased risk of childhood ALL with adjusted HR = 0.87 (95% confidence interval [CI]: 0.65-1.16). Risk estimates did neither vary statistically significantly by age at enrolment nor by type of childcare facility and also not between childhood ALL subtypes, including frequently prenatally initiated ALL subtypes. Results from this large, nationwide register-based study provided no evidence that childcare attendance in the first years of life protects against childhood ALL. 相似文献
19.
20.
《International journal of hygiene and environmental health》2019,222(6):945-954
BackgroundPrenatal exposure to perfluoroalkyl substances (PFASs) has been associated with impaired immune and respiratory health during childhood but the evidence is inconsistent and limited for lung function. We studied the association between prenatal PFASs exposure and immune and respiratory health, including lung function, up to age 7 years in the Spanish INMA birth cohort study.MethodsWe assessed four PFASs in maternal plasma samples collected during the 1st trimester of pregnancy (years: 2003–2008): perfluorohexane sulfonate (PFHxS), perfluorooctane sulfonate (PFOS), perfluorooctanoate (PFOA), and perfluorononanoate (PFNA). Mothers reported the occurrence (yes/no) of lower respiratory tract infections, wheezing, asthma, and eczema in the previous 12 months at 1.5 and 4 years of the child (n = 1188) and at 7 years (n = 1071). At ages 4 (n = 503) and 7 (n = 992) years lung function was assessed using spirometry tests.ResultsThe most abundant PFASs were PFOS and PFOA (geometric means: 5.80 and 2.31 ng/mL, respectively). The relative risk of asthma during childhood per each doubling in PFNA concentration was 0.74 (95 CI%: 0.57, 0.96). The relative risk of eczema during childhood per every doubling in PFOS concentration was 0.86 (95 CI%: 0.75, 0.98). Higher PFOA concentrations were associated with lower forced vital capacity and lower forced expiratory volume in 1 s z-scores at 4 years [β (95 CI %): −0.17 (−0.34, −0.01) and −0.13 (−0.29, 0.03), respectively], but not at 7 years.ConclusionThis longitudinal study suggests that different PFASs may affect the developing immune and respiratory systems differently. Prenatal exposure to PFNA and PFOS may be associated with reduced risk of respiratory and immune outcomes, particularly asthma and eczema whereas exposure to PFOA may be associated with reduced lung function in young children. These mixed results need to be replicated in follow-up studies at later ages. 相似文献